Skip to main content

Table 3 Prognostic factors for overall survival according to univariate and multivariate analyses in patients with wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy

From: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy

n = 131

Univariate

 

Multivariate

 

Variable

Hazard ratios (95% CI)

P-value

Hazard ratios (95% CI)

P-value

Age > 65 (y/o)

1.045 (0.627–1.742)

0.865

—

—

Initial stage IV at diagnosis

1.660 (0.999–2.757)

0.050

1.445 (0.856–2.439)

0.168

Bilobar liver metastases

1.049 (0.477–2.308)

0.905

—

—

Size > 5 cm

0.865 (0.411–1.820)

0.703

—

—

Number > 3

2.045 (1.167–3.586)

0.013

2.084 (1.200–3.621)

0.009

High grade

1.863 (1.032–3.362)

0.039

2.031 (1.101–3.744)

0.023

Margin R2

3.559 (1.092–11.600)

0.035

3.701 (1.111–12.330)

0.033

Extrahepatic metastasis

1.472 (0.782–2.771)

0.231

—

—

CIP2A over-expression

1.751 (1.041–2.946)

0.035

2.109 (1.236–3.600)

0.006

  1. Abbreviations: CIP2A Cancerous inhibitor of protein phosphatase 2A, KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog.